Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > 1300 shares traded
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Comment by canadapieton Jun 11, 2021 12:27pm
164 Views
Post# 33372709

RE:1300 shares traded

RE:1300 shares tradedSomeone earlier on said trading wasn't a problem with this low volume ....

Am trying to sell 10.000 shares, wtf.....!!!
Manmanman, what a misery! 

 
SPCEO:
I would not let the current low volume think you cannot trade the stock.
I have owned it forever and owned it in size. Even when the stock was a
$30 million market cap stock many years back, I was.......


jeffm34 - (6/11/2021 12:05:32 PM) 
1300 shares traded
2.5 hrs of trading on the TSX this morning and 1300 shares have traded hands. This company is completely invisible.  Too bad we gave up our only opportunity to effect any meaningful change. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities